ibritumomab tiuxetan
(ih-brih-TOO-moh-mab ty-UK-seh-tan)
A drug used to
treat adults with certain types of B-cell non-Hodgkin
lymphoma. It is also being studied in the treatment of
other types of cancer. Ibritumomab tiuxetan
contains a monoclonal antibody that binds to a protein
called CD20, which is found on B cells and some types of
lymphoma cells. It also contains the compound tiuxetan,
which allows certain radioactive substances to be attached
to the monoclonal antibody. This may help kill cancer
cells. Ibritumomab tiuxetan is a type of
monoclonal antibody and a type of
immunoconjugate. Also called Zevalin.